Your browser is no longer supported. Please, upgrade your browser.
Settings
MDVN Medivation, Inc. daily Stock Chart
MDVN [NASD]
Medivation, Inc.
Index- P/E41.65 EPS (ttm)1.38 Insider Own1.10% Shs Outstand163.79M Perf Week11.00%
Market Cap9.42B Forward P/E29.38 EPS next Y1.96 Insider Trans-4.87% Shs Float162.21M Perf Month30.19%
Income244.70M PEG1.29 EPS next Q0.23 Inst Own93.80% Short Float2.17% Perf Quarter83.30%
Sales943.30M P/S9.99 EPS this Y-11.10% Inst Trans0.23% Short Ratio0.95 Perf Half Y36.76%
Book/sh5.33 P/B10.79 EPS next Y48.00% ROA22.70% Target Price50.44 Perf Year-7.92%
Cash/sh- P/C- EPS next 5Y32.23% ROE38.50% 52W Range26.41 - 66.39 Perf YTD18.99%
Dividend- P/FCF47.01 EPS past 5Y50.90% ROI27.10% 52W High-11.63% Beta0.96
Dividend %- Quick Ratio2.40 Sales past 5Y72.10% Gross Margin- 52W Low122.15% ATR2.82
Employees628 Current Ratio2.40 Sales Q/Q37.50% Oper. Margin41.70% RSI (14)72.87 Volatility3.89% 4.41%
OptionableYes Debt/Eq0.09 EPS Q/Q-19.10% Profit Margin25.90% Rel Volume2.35 Prev Close57.52
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout0.00% Avg Volume3.71M Price58.67
Recom2.20 SMA2014.08% SMA5034.33% SMA20035.76% Volume2,606,299 Change2.00%
May-02-16Reiterated Stifel Buy $52 → $66
May-02-16Reiterated Jefferies Hold $39 → $52
Apr-29-16Reiterated Wedbush Outperform $47 → $59
Apr-06-16Initiated Sun Trust Rbsn Humphrey Buy $56
Mar-31-16Reiterated Credit Suisse Outperform $48 → $49
Mar-30-16Initiated Goldman Neutral
Feb-19-16Initiated BofA/Merrill Buy
Feb-01-16Reiterated Wedbush Outperform $59 → $47
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $90 → $45
Jan-21-16Initiated Credit Suisse Outperform
Nov-10-15Reiterated Maxim Group Buy $74 → $54
Nov-09-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Nov-06-15Reiterated UBS Buy $74 → $68
Nov-06-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Sep-28-15Reiterated Maxim Group Buy $171 → $74
Sep-16-15Initiated Nomura Buy
Sep-03-15Initiated Citigroup Neutral
Aug-25-15Reiterated UBS Buy $145 → $148
Jul-30-15Reiterated Stifel Buy $146 → $107
Jun-04-15Reiterated Maxim Group Buy $155 → $168
May-04-16 10:25AM  Pfizer eyes this San Francisco biotech involved in tight acquisition war at American City Business Journals
10:16AM  Sanofi says sees "strong strategic" fit with U.S. cancer firm Medivation Reuters
10:11AM  Who Will Win Medivation: Pfizer or Sanofi? Yahoo Finance Contributors
09:23AM  Stocks Open Modestly Lower; Priceline Dives, Paycom Soars at Investor's Business Daily
09:18AM  Deals of the Day: MultiPlan Sale Looms, ICE Says No to LSE Bid at The Wall Street Journal
08:58AM  Tesla on deck, Etsy surges, BHP and Vale hit with $44B lawsuit Yahoo Finance
08:14AM  Pfizer Reportedly Approaches Drugmaker Medivation About a Buyout at TheStreet
07:58AM  Stocks fall again, Trump victory Yahoo Finance
07:54AM  Early movers: TWX, PCLN, ENR, GNRC, KSS, CBS, FCAU, Z, ETSY, UA & more at CNBC
05:52AM  May 4 Premarket Briefing: 10 Things You Should Know at TheStreet
03:34AM  Dollar seesaw, earnings to grab limelight on Wall Street at CNBC
May-03-16 06:33PM  Forget Allergan: Pfizer Has Its Sights On This Cancer Drugmaker at Investor's Business Daily
06:04PM  Exclusive: Pfizer approaches Medivation about potential takeover - sources Reuters
05:41PM  What Sent Medivation, Inc.'s Shares Soaring 25.1% In April at Motley Fool
11:53AM  Medivation: Sanofi's Bid 'Significantly Undervaluing' Pipeline at Barrons.com
07:00AM  Medivation Announces First Quarter 2016 Financial Results Teleconference on May 5, 2016 Marketwired
May-02-16 04:17PM  Weekly Mid-Cap Update: Medivation Rose, Rejected Sanofis Offer Market Realist
11:28AM  Medivation: Why a Takeover Just Got a Little Tougher at Barrons.com
09:48AM  As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A at Forbes
08:25AM  Top Analyst Upgrades and Downgrades: Chevron, Colgate-Palmolive, Groupon, Medivation, Microsoft, Seagate and More at 24/7 Wall St.
06:14AM  MEDIVATION, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articles of I EDGAR Online
Apr-29-16 07:08PM  [$$] Sanofi Seeks Talks With Medivation Over $9.3 Billion Offer at The Wall Street Journal
05:05PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
02:38PM  Here's What Medivation Said In Its Rejection Letter To Sanofi Benzinga
12:30PM  AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bid at Bloomberg
11:50AM  Medivation's Right to Play Hard-To-Get at Bloomberg
11:28AM  Resource And Biotech Stocks On The Rise at Forbes
10:56AM  [$$] Medivation Rejects Sanofi's Takeover Bid at The Wall Street Journal
10:50AM  Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation at TheStreet
10:17AM  Medivation Rejects Sanofis Buyout Bid; Sanofi Remains Committed at Investor's Business Daily
10:11AM  Sanofi, Medivation dig in for big biotech takeover battle Reuters
09:39AM  Medivation just rejected Sanofi's $9.3 billion takeover bid Business Insider
09:19AM  Medivation board rejects Sanofi's $9.3 billion takeover offer Reuters
09:16AM  Sanofi says committed to Medivation takeover Reuters
09:05AM  Medivation board rejects Sanofi's $9.3 bln takeover offer Reuters
09:00AM  Medivation Rejects Sanofi's Unsolicited $9.3 Billion Offer at Bloomberg
08:45AM  Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal Marketwired
04:52AM  Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation Reuters
01:40AM  Sanofi confident can win Medivation shareholder support for bid Reuters
01:30AM  Sanofi Profit Little Changed as Drugmaker Pursues Medivation at Bloomberg
12:38AM  [$$] Drugmakers Place Big Bets on Cancer Medicines at The Wall Street Journal
12:38AM  [$$] Abbott Agrees to Buy St. Jude in $25 Billion Deal at The Wall Street Journal
Apr-28-16 07:13PM  [$$] Abbott Agrees to Buy St. Jude in $25 Billion Deal at The Wall Street Journal +7.92%
05:34PM  [$$] Drugmakers Place Big Bets on Cancer Medicines at The Wall Street Journal
04:40PM  Stocks End Sharply Lower; Amazon Surges Late On Earnings at Investor's Business Daily
04:23PM  Medical M&A Rules The Day As Abbott, AbbVie Make Buys, Sanofi Bids at Investor's Business Daily
04:17PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:05PM  Big Pharma grooves $20 billion M&A dance with 2 Bay Area biotechs at American City Business Journals
03:01PM  Takeover Thursday CNBC
02:36PM  Dealpolitik: Different Defense Playbooks for Tribune, Medivation at The Wall Street Journal
02:29PM  Sanofi's Bid for Medivation Is Too Low at Motley Fool
01:41PM  [$$] Three pharma deals worth $45bn reignite M&A boom at Financial Times
01:05PM  Sanofi launches $9.3 blillion fight for U.S. cancer firm Medivation Reuters
01:03PM  Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Reuters
11:50AM  Why Investors Are Buzzing About These Stocks Today at Insider Monkey
11:49AM  Sanofi makes $9.3 billion bid for American firm Medivation AP
10:55AM  Sanofi Goes Public With $9.3 Billion Bid For Cancer Drugmaker Medivation at Investor's Business Daily
10:27AM  Medivation (MDVN) Stock Surges on Sanofi Bid at TheStreet
10:21AM  [$$] Sanofi / Medivation: Deal-Making Déjà Vu Comes With Added Competition at The Wall Street Journal
10:17AM  Medivation shares rise above Sanofi takeover bid at CNBC
10:11AM  Sanofi Wants To Acquire Medivation For $52.50 Per Share Benzinga
09:46AM  Stocks Mixed In Early Going; St. Jude Medical, Facebook Jump at Investor's Business Daily
09:24AM  Facebook surges to new high, Priceline CEO steps down Yahoo Finance
09:12AM  Medivation Confirms Receipt of Unsolicited Proposal From Sanofi Marketwired
08:25AM  Sanofi makes $9.3-billion bid for San Francisco drug company Medivation at Los Angeles Times
08:15AM  Early movers: STJ, F, FB, DNKN, AET, RTN, BZH, CAB, PYPL & more at CNBC
08:10AM  GDP disappoints, BOJ surprise Yahoo Finance
07:00AM  Sanofi Presses Medivation to Hold Talks After $9.3B Offer at TheStreet
06:25AM  [$$] Sanofi Makes $9.3 Billion Bid for U.S. Cancer Drugmaker at The Wall Street Journal
04:38AM  Sanofi Offers to Acquire Medivation for $52.50/Share in Cash Benzinga
03:04AM  Opportunities For Xtandi, Medivations Key Drug Market Realist
02:17AM  France's Sanofi makes $9.3 bln bid for U.S. biotech Medivation Reuters
02:07AM  Sanofi Stalks Medivation With $9.3 Billion on Being Spurned at Bloomberg
Apr-27-16 04:10PM  Medivation Announces Participation at Upcoming Investor Conferences Marketwired
08:01AM  J&J's Q1 Results Suggest More Upside for Medivation, Inc. at Motley Fool
Apr-26-16 10:05AM  4 Biotechs That Will Escape Weak Seasonal Trends for the Sector at 24/7 Wall St.
Apr-22-16 01:23PM  3 Stocks to Buy in a Crashing Market at Motley Fool
Apr-21-16 04:10PM  Medivation Announces First Quarter 2016 Financial Results Teleconference on May 5, 2016 Marketwired
09:30AM  The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen Zacks
Apr-20-16 06:05PM  Xtandi: A Major Prostate Cancer Drug Market Realist
06:05PM  XBI Mid-Caps: Medivation Rose after Rejecting Sanofis Takeover Bid Market Realist
06:05PM  Medivations Key Assets: Talazoparib and Pidilizumab Market Realist
06:05PM  Is Sanofi Trying to Acquire Medivation? Market Realist
04:38PM  Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal Zacks
09:07AM  Mid-Caps: Medivation Presents Phase 1 Talazoparib Data Market Realist
09:00AM  Medivation Announces Presentation of Phase 2 Enzalutamide Data Evaluating Potential Immune-Activating Properties in Non-Metastatic Castration Sensitive Prostate Cancer Patients Marketwired
Apr-19-16 09:06AM  What Do Analysts Recommend for Medivation?
Apr-18-16 12:15PM  Medivation Rises On Cancer Drug Data, AstraZeneca Buyout Rumor
11:07AM  Could Xtandis Use for Breast Cancer Be a Valuation Driver?
10:34AM  Medivation (MDVN) Stock Surges on Takeover Speculation at TheStreet
09:44AM  The Market In 5 Minutes: Brazil, Doha, And Earnings Season
09:39AM  Medivation: It's Not Just M&A at Barrons.com
09:32AM  Term Sheet Monday, April 18 at Fortune
07:53AM  Early movers: MS, PEP, HAS, ATHM, C, DIS, TM & more at CNBC
Apr-17-16 08:06PM  PRESS DIGEST- British Business - April 18
05:30PM  Medivation Announces Presentation of Phase I Talazoparib Combination Data in Several Advanced Cancers Marketwired
Apr-16-16 11:00AM  3 Biotech Stocks With Charts to Watch -- And One Bonus Stock! at TheStreet
Apr-15-16 10:39AM  XBI Holdings Finished Strong as Market Bounced Back on April 13
Apr-14-16 07:05PM  Why Is Medivation at a Premium on an EV-to-EBITDA Basis?
07:03PM  How Does Medivations Cancer Drug Xtandi Affect Its Valuation?
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer. In addition, it develops Talazoparib, which is in phase II clinical trials for treatment of germline mutated HER2 normal breast cancer; Pidilizumab that is in phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and MDV4463, which is in phase I clinical trials for the treatment of nonalcoholic steatohepatitis. The company has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. Medivation, Inc. is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Svoronos DawnDirectorMar 14Sale38.906,000233,40018,234Mar 16 05:06 PM
Hirmand MohammadInterim Chief Medical OfficerMar 04Sale41.101,52562,68539,342Mar 07 08:44 PM
Bierly RickChief Financial OfficerMar 04Sale40.002,998119,92039,084Mar 07 08:43 PM
Hung DavidPresident and CEOFeb 04Sale31.186,350197,9931,504,654Feb 05 07:05 PM
Machado Clarence PatrickDirectorJan 19Option Exercise3.3775,000252,525141,156Jan 21 05:45 PM
Machado Clarence PatrickDirectorJan 19Sale37.3475,0002,800,56266,156Jan 21 05:45 PM
Lobacki Joseph MChief Commercial OfficerJan 04Sale46.503,065142,52319,365Jan 05 06:14 PM
VERNON W ANTHONYDirectorDec 14Buy40.6915,000610,35028,704Dec 16 05:40 PM
Hung DavidPresident and CEODec 03Sale43.1010,950471,9661,511,004Dec 04 04:36 PM
Hirmand MohammadInterim Chief Medical OfficerDec 03Sale43.401,07546,65531,113Dec 04 04:35 PM
Hirmand MohammadInterim Chief Medical OfficerNov 09Sale41.912329,72232,188Nov 12 06:46 PM
Svoronos DawnDirectorSep 08Sale89.153,100276,36512,117Sep 08 07:39 PM
Machado Clarence PatrickDirectorJun 04Option Exercise9.3936,000337,86067,500Jun 08 06:25 PM
Machado Clarence PatrickDirectorJun 04Sale117.4336,0004,227,47831,500Jun 08 06:25 PM
Bierly RickChief Financial OfficerMay 20Sale130.001,000130,00014,841May 20 06:40 PM
Bierly RickChief Financial OfficerMay 08Sale125.0038548,12515,841May 12 08:07 PM
Bierly RickChief Financial OfficerMay 05Sale125.001,615201,87516,226May 06 07:42 PM